bulevirtide
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Blue Earth Diagnostics's portfolio. Mechanism: Bile acid transporter inhibitor.
- Mechanism
- Bile acid transporter inhibitor
pharma · Chronic Hepatitis D Infection · Chronic Hepatitis Delta Infection
Blue Earth Diagnostics Ireland Ltd
Blue Earth Diagnostics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Blue Earth Diagnostics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antiinfectives for systemic use (J05) compound in Blue Earth Diagnostics's portfolio. Mechanism: Bile acid transporter inhibitor.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Various (V10) compound in Blue Earth Diagnostics's portfolio. Mechanism: Diagnostic agent.
Various (V10) compound in Blue Earth Diagnostics's portfolio. Molecular target: DNA.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.
Development asset linked to Blue Earth Diagnostics in public FDA and regional records.